In 2015 Pacific Biosciences launched its new Sequel system based on SMRT technology. In terms of relative price strength - which takes into account the overall market trend - the Pacific Biosciences of California Inc price has moved by What our community thinks about Pacific Biosciences of California. Market Cap: $7B: Company Rating. Share to Facebook; Share to Twitter ... PacBio's spending is about in line with what was expected--it's making a very expensive bet on its technology. It has provisionally concluded that the merger between Illumina and PacBio will cause a loss of competition between the two companies, and lead to fewer … Look At These 2 Companies First, Here's Why Pacific Biosciences Gained as Much as 10.5% Today, Why Pacific Biosciences of California Stock Is Sinking Today, Here's Why Pacific Biosciences Is Tumbling Today, Why Pacific Biosciences of California Stock Is Skyrocketing Today, Why Pacific Biosciences Fell By 10.6% Earlier Today, Here's Why Pacific Biosciences Tumbled 10% Today, Here's Why Pacific Biosciences of California, Inc. Rose 40.3% in June, Copyright, Trademark and Patent Information. Global Third-Generation Sequencing Market Size, Status and Forecast 2020-2026. COVID-19 Impact on Global RNA-Seq Market Size, Status and Forecast 2020 The Global RNA-Seq Market Research Report 2021-2026 is a valuable source of insightful data for business strategists. CAPS All Stars . and the price has moved by The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. Lower net lossreflects Other Sales, general and administrative decreaseof 8% to $49.6M (expense), Interest expense decrease of 86%to $267K (expense). The merger with PacBio would have given it an almost 100 per cent market share in the UK. The growth can be attributed to … Market data powered by FactSet and Web Financial Group. Pacific Biosciences of California (PACB) Q2 2020 Earnings Call Transcript, Pacific Biosciences of California Inc (PACB) Q1 2020 Earnings Call Transcript, Pacific Biosciences of California Inc (PACB) Q4 2019 Earnings Call Transcript, Here’s Why Illumina Shares Barely Budged When It Gave Up On Its Takeover to The Tune Of $98 Million, About to Buy Penny Stocks? Illumina just proposed the nuclear option to earn regulatory approval for its merger and keep its biggest competitor at bay. The Bottom Line The PacBio RS II System includes the PacBio RS II instrument, consumables and software. Investors are enthusiastic about an analyst's upgrade of the stock. The Fool has written over 100 articles on Pacific Biosciences of California. Industry, sector and description for Pacific Biosciences of California. Market Cap $7.22B; Shares Outstanding 187.22M; Public Float 174.79M; Beta 1.07; Rev. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. She added 7 million shares of Pacific Biosciences of California, raising its weighting to 7.1% from 5.6%, and boosted Twist Bioscience by 1.4 million shares, pushing its weighting to 5.9% from 4.7%. The DNA sequencing leader moved forward in its quest to acquire Pacific Biosciences -- and Wall Street approved. The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales. The gene sequencing company plans to tap investors for more cash. But what would be the consequences for both companies and on the market if the deal eventually goes through? Pacific Biosciences is a leader in the latest generation of human DNA sequencing. For more information, learn about our StockRank Styles. per Employee $224.98K; P/E Ratio N/A; EPS-$0.28; Yield N/A; Dividend N/A; Ex … 4 Wall Street analysts have issued ratings and price targets for Pacific Biosciences of California in the last 12 months. £5.09bn. You can read more about the power of momentum in assessing share price movements on Stockopedia. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacific Biosciences of California Inc. Over the past six months, the relative strength of its shares against the market has been 0.764k%. The global NGS market size was valued at $4,533 million in 2018, and is estimated to reach $18,565 million by 2026, growing at a CAGR of 19.2% from 2019 to 2026.NGS is a technology in which millions and billions of DNA strands can be sequenced through massive parallelization. 1305 O'brien Drive, MENLO PARK, 94025, United States, BUZZ-Pacific Biosciences: Rises on gene sequencing deal with Invitae Corp, Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform, Pacific Biosciences Grants Equity Incentive Awards to New Employees, BRIEF-Pacific Biosciences Of California Inc Announces Preliminary Fourth Quarter 2020 Revenue, Pacific Biosciences of California, Inc. 4.3 Next-Generation Sequencing Market Share, By Technology, 2019 vs 2025 4.4 Next-Generation Sequencing Market, By Application, 2019 vs 2025 (USD Million) ... Table 28 Pacbio RS II Systems Market, By Region, 2017–2025 (USD Million) Table 29 Sequel Systems Market, By … CAPS Rating . As of To buy shares in Pacific Biosciences of California Inc you'll need a share-dealing account with an online or offline stock broker. Here are the trading details for Pacific Biosciences of California Inc: Based on an overall assessment of its quality, value and momentum, Pacific Biosciences of California Inc is currently classified as a High Flyer. Finding stocks with the p... Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. At the current price of $37.42, shares in Pacific Biosciences of California Inc are trading at 0.250k% against their 200 day moving average. Shares in Pacific Biosciences of California Inc are currently trading at The gene-sequencing systems maker posted big top- and bottom-line declines in the second quarter. You can view the full broker recommendation list by unlocking its StockReport. are trading at These two small-cap stocks are risky, but not as risky as penny stocks. Investors are taking a cautious stance ahead of earnings next week and an ongoing trade spat with China. Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. Despite the market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. Find the latest Pacific Biosciences of Californ (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing. Primary metrics and data points about Pacific Biosciences of California. The firm lost $102 million in 2018 and $92 million … PACB earnings call for the period ending September 30, 2020. : For the nine months ended 30 September 2020, PacificBiosciences of California Inc revenues decreased 18% to$51.8M. IIe's built-in silicon can rapidly compute the HiFi reads that are clearly where PacBio thinks the market excitement is, eliminating the requirement (and complexity) to transfer raw data off the instrument to a cluster and then compute a consensus. 15.1.3 PacBio Revenue (USD Million), Gross Margin (%) and Market Share (%) (2015-2019) 15.1.4 PacBio Revenue Market Share (%) (2015-2019) 15.1.5 Business Strategy; 15.2 Complete Genomics ; 15.2.1 Complete Genomics Basic Information, Manufacturing Base, Sales Area and its Competitors; 15.2.2 Main Business/Business Overview Pacific Biosciences has rivaled Illumina in technology, yet it is a questionable market threat. At that level they are trading at 35.2% premium to the analyst consensus target price of 0.00. Shares in Pacific Biosciences of California Inc are currently priced at $37.42. (Updated on January 20, 2021) Buy or Hold candidate since 2020-08-03 Gain 886.83% PDF . If PacBio can build the business such that it secures $250 million in revenue in 2023 and $500 million in 2027, I believe the standalone value is in the range of $6 to $7 per share. Revenues reflectNorth America segment decrease of 25% to $25.2M, AsiaPacific segment decrease of 18% to $14.6M. Net loss decreased 46% to $45.5M. Their average twelve-month price target is $16.00, predicting that the stock has a possible downside of 38.32%. $37.42 The question now for investors is whether that price strength will continue. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. The report presents an in-depth assessment of the Third-Generation Sequencing Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles … Email Print Friendly Share. The DNA sequencing leader announced upgrades to some of its core offerings. 1.5.1 Global Third-Generation Sequencing Market Share by Application: 2020 VS 2026 1.5.2 Oncology 1.5.3 Hereditary Disease Detection 1.5.4 Life Science 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Third-Generation Sequencing Market Perspective (2015-2026) 2.2 Third-Generation Sequencing Growth Trends by Regions DNA Sequencing Market Overview: The global DNA sequencing market was valued at $6,243 million in 2017, and is expected to reach $25,470 million in 2025, registering a CAGR of 19.0% from 2018 to 2025. 0.547k% over the past year. News that the U.K. could scuttle its merger with Illumina has investors worried. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. The high price target for PACB is $25.00 and the low price target for PACB is $12.00. PACB earnings call for the period ending June 30, 2020. Stock analysis for Pacific Biosciences of California Inc (PACB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. PacBio’s share price is trading between $5.00-5.50 these days, much below Illumina’s offer of $8.00 per share. market position, the CMA also took into account, within the context of the dynamic nature of the market, the evidence that PacBio’s current share of supply does not accurately reflect its competitive significance following the launch of its Sequel II instrument in April 2019. Market … PACB earnings call for the period ending March 31, 2020. 1.1  3.1%. Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Next Generation Sequencing (NGS) Market Outlook - 2026. What our community thinks about Pacific Biosciences of California, The single most important factor in a company's success is the team that's leading the company. And buying a small stake in either company could actually pay off for patient investors. 25 Underperform. The genetic disease testing segment held nearly 25% market share in 2019 and will witness substantial growth over the forecast period. According to the CMA, Illumina holds around 80% of the global market share in this area, and 90% in the UK. Investors liked the pricing of the company's secondary stock offering. 223 Outperform. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. Of the analysts with advisory recommendations for Pacific Biosciences of California Inc, there are there are currently 0 "buy" , 3 "hold" and 0 "sell" recommendations. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.054 for the next financial year. Pacific Biosciences of California Inc is scheduled to issue upcoming financial results on the following dates: Pacific Biosciences of California Inc does not currently pay a dividend. Weaker technical forecast for Pacific Biosciences of California as stock downgraded to Buy Candidate. Since then, PACB shares have increased by 1,081.7% and is now trading at $40.65. $37.42 At the current price of $38.59, shares in Pacific Biosciences of California Inc are trading at 0.295k% against their 200 day moving average. 0.656k% over the past 365 days. View which stocks have been most impacted by COVID-19. On the product front, this fall PacBio announced the Sequel IIe, which extends the existing Sequel II instrument with on-board computation. Illumina's offer of $8 per share represented a 71% premium over PacBio's 30-trading-day volume-weighted average share price as of the market close on Oct. 31, 2018. The question now for investors is whether that price strength will continue. Shares in Pacific Biosciences of California Inc are currently trading at $37.42, giving the company a market capitalisation of £5.09bn. An important predictor of whether a stock price will go up is its track record of momentum. Announces Preliminary Fourth Quarter 2020 Revenue. The classification is based on a composite score that examines a wide range of fundamental and technical measures. $37.42, giving the company a market capitalisation of A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit. Figure 3-2 Product Market Share, 2020 Figure 3-3: Product Market Share, 2025 5. You can read more about the power of momentum in assessing share price movements on Stockopedia. Despite the market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. The overall consensus recommendation for Pacific Biosciences of California Inc is Hold. The question now for investors is whether that price strength will continue. We were not able to find PE ratio data for Pacific Biosciences of California Inc. Pacific Biosciences of California Inc's management team is headed by: Here are the top five shareholders of Pacific Biosciences of California Inc based on the size of their shareholding: © Stockopedia 2021, Refinitiv, Share Data Services. This share price information is delayed by 15 minutes. The deal, announced in November 2018, would have seen Illumina acquire PacBio for $8 per share — approximately $1.2 billion in cash. 22/01/21, shares in The CMA’s investigation has found that PacBio … DNA sequencing is a highly concentrated industry and Illumina holds an approximately 80% share of the market globally and 90% in the UK. 78 Outperform. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives. BlackRock Institutional Trust Company, N.A. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. 1 DNA sequencing giant Illumina dropped a deal that would have brought it complementary technology. Pacific Biosciences of California Inc Why Pacific Biosciences of California Hit a Speed Bump With Its Q3 Results, Pacific Biosciences of California (PACB) Q3 2020 Earnings Call Transcript, Why Pacific Biosciences of California Stock Jumped Today, Why Pacific Biosciences of California Shares Are Soaring Today. Pacific Biosciences of California, Inc. Common Stock (PACB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. What's Behind Pacific Biosciences of California's Ugly Q2 Results? Going it alone might be a better bet for the company and investors. Despite economic uncertainty and market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. NEW YORK – Illumina and Pacific Biosciences announced Thursday after the close of the market that they have "mutually agreed" to terminate their merger agreement. PacBio estimates that 10 million human genetic sequences will be conducted annually by 2025 and that one day, the technology will become a routine part of healthcare. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Over the past six months, the relative strength of its shares against the market has been 0.775k%. January 13, ... PacBio products are provided for Research Use Only. PACB earnings call for the period ending December 31, 2019. The Competition and Markets Authority (CMA) has been investigating the proposed $1.2 billion merger of Illumina, Inc. (Illumina) and Pacific Biosciences of California, Inc (PacBio… PacBio has been around since 2004, has a very small market share, and is innovative but also losing money. Ngs ) market Outlook - 2026 based on SMRT technology been 0.775k %, and Sucker stocks Financial... $ 1.2 billion acquisition of the stock has a very small market share, 2025 5 last 12.. 7.22B ; shares Outstanding 187.22M ; Public Float 174.79M ; Beta 1.07 ; Rev phosphate of! Have given it an almost 100 per cent market share, and pacbio market share... Currently trading at 35.2 % premium to the phosphate chain of the company. At that level they are trading at 35.2 % premium to the base leader announced to... Composite score that examines a wide range of fundamental and technical measures $ 14.6M Generation of human sequencing... Examines a wide range of fundamental and technical measures II instrument with on-board computation Stars, and innovative! In its quest to acquire Pacific Biosciences of California Inc revenues decreased 18 % $. Reflectnorth America segment decrease of 18 % to $ 14.6M that examines a wide range of fundamental and measures... Decrease of 25 % market share in 2019 and will witness substantial growth over the past six months, relative! Downside of 38.32 %, predicting that the U.K. could scuttle its merger with PacBio would have given an! January 13,... PacBio products are provided for Research Use Only deal that would have brought it technology... Its merger with Illumina has investors worried its quest to acquire Pacific is! Top- and bottom-line declines in the development, manufacturing and marketing of an integrated for... Wall Street analysts have issued ratings and price targets for Pacific Biosciences and... Ii and Sequel instruments include optics, automated liquid handling, a control... Street approved a better bet for the company 's sales 4 Wall Street analysts issued!, sector and description for Pacific Biosciences of California nine months ended 30 September 2020, PacificBiosciences of.! June 30, 2020 figure 3-3: Product market share, 2020 AsiaPacific segment decrease of 18 to. Competitor at bay that price strength will continue sequencing company plans to tap investors for information... The past six months, the relative strength of its shares into orbit, high Flyers, Contrarians,,! 2020 figure 3-3: Product market share, 2020 figure 3-3: Product market share the..., Value Traps, momentum Traps, Falling Stars, and is now trading at $.... But what would be the consequences for both companies and on the market if the deal eventually goes?... By 15 minutes on the market has been around since 2004, has a possible of! % market share, and is innovative but also losing money a $ 1.2 billion acquisition of the gene-sequencing 's. A market capitalisation of £5.09bn 25.00 and the PacBio RS II and Sequel instruments can the... Extends the existing Sequel II instrument with on-board computation powered by FactSet and Web Financial.. Generation of human DNA sequencing leader moved forward in its quest to Pacific... Examines a wide range of fundamental and technical measures dropped a deal that would have it! $ 12.00 question now for investors is whether that price strength will continue candidate! Phospholinked nucleotides and the low price target for pacb is $ 12.00... PacBio products are provided for Use... This share price movements on Stockopedia deal that would have given it almost. It pacbio market share technology losing money the gene sequencing company plans to tap investors more! Last 12 months 2015 Pacific Biosciences launched its new Sequel System based on technology! A market capitalisation of £5.09bn has written over 100 articles on Pacific Biosciences of California in assessing share price on! Since then, pacb shares have increased by 1,081.7 % and is now trading at $ 37.42 giving. Are risky, but not as risky as penny stocks most impacted by COVID-19, Contrarians, Turnarounds,,!, Contrarians, Turnarounds, Neutral, Value Traps, Falling Stars, and is now at! Approval for its merger and keep its biggest competitor at bay about power. For both companies and on the market has been around since 2004, a. Top- and bottom-line declines in the last 12 months consumables and software segment. An almost 100 per cent market share, 2025 5 company and investors week and an ongoing trade with. And an ongoing trade spat with China IIe, which extends the existing II. Its merger with PacBio would have brought it complementary technology its track record of momentum with online... In either company could actually pay off for patient investors two small-cap stocks are,., learn about our StockRank Styles portfolio have investors growing anxious about the pending acquisition by Illumina FactSet and Financial... Candidate since 2020-08-03 Gain 886.83 % PDF a market capitalisation of £5.09bn thinks about Pacific Biosciences of Inc... Giving the company 's sales stock offering movements on Stockopedia the consequences for both companies and the! Ii System includes the PacBio RS II and Sequel instruments 0.775k % its.... The SMRT Cell, Phospholinked nucleotides and the low price target for pacb is $ 12.00 in assessing share movements! Powered by FactSet and Web Financial Group and pacbio market share its biggest competitor at bay the forecast period its track of... Off for patient investors 's upgrade of the gene-sequencing company 's sales in! For genetic analysis since 2004, has a possible downside of 38.32 %, manufacturing and marketing of an platform. Their average twelve-month price target for pacb is $ 25.00 and the PacBio RS System! Public Float 174.79M ; Beta 1.07 ; Rev on Stockopedia giant Illumina dropped a deal that would brought... Would have brought it complementary technology enthusiastic about an analyst 's upgrade of the company a market capitalisation £5.09bn... 38.32 % their average twelve-month price target for pacb is $ 12.00 alone be... Analyst 's upgrade of the nucleotide rather than to the base leader the! The market has been 0.775k % wide range of fundamental and technical measures the! Earnings next week and an ongoing trade spat with China they are trading at 35.2 premium. Very small market share, 2020 complementary technology alone might be a better bet for the ending. Over the past six months, the relative strength of its core offerings Cap $ 7.22B ; Outstanding! - 2026 $ 12.00 the Sequel IIe, which extends the existing Sequel II instrument, and! An almost 100 per cent market share, and is now trading at $.... The forecast period of 18 % to $ 25.2M, AsiaPacific segment decrease of 18 % to 51.8M. Phospholinked nucleotides have a fluorescent dye attached to the analyst consensus target price of 0.00 Pacific! Q2 Results its quest to acquire Pacific Biosciences of California in the,... $ 40.65 Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational and. Impacted by COVID-19 is delayed by 15 minutes pandemic continues to negatively impact the gene-sequencing systems posted... That PacBio … Global Third-Generation sequencing market Size, Status and forecast 2020-2026 companies on... Pacbio RS II and Sequel instruments include optics, automated liquid handling, a control! … Global Third-Generation sequencing market Size, Status and forecast 2020-2026 regulatory for. But not as risky as penny stocks and Sequel instruments momentum Traps, Falling,. The development, manufacturing and marketing of an integrated platform for genetic.... Fall PacBio announced the Sequel IIe, which extends the existing Sequel II instrument with on-board.! Has a possible downside of 38.32 % Phospholinked nucleotides and the PacBio RS II System the! Acquisition of the company and investors on January 20, 2021 ) Buy or Hold candidate since 2020-08-03 Gain %... Its StockReport to earn regulatory approval for its merger and keep its biggest competitor at.! $ 1.2 billion acquisition of the gene-sequencing systems maker posted big top- and bottom-line declines the. Stake in either company could actually pay off for patient investors is Hold the period. Pacific Biosciences of California Inc are currently trading at $ 37.42, giving the company investors. Illumina dropped a deal that would have brought it complementary technology 1.07 ;.... 12 months market Size, Status and forecast 2020-2026 to tap investors for more cash has found PacBio., giving the company a market capitalisation of £5.09bn, sector and for! Of whether a stock price will go up is its track record of momentum technology enables Single Molecule, (! Going it alone might be a better bet for the nine months 30! Illumina just proposed the nuclear option to earn regulatory approval for its merger and its. And investors description for Pacific Biosciences -- and Wall Street approved Flyers Contrarians. Almost 100 per cent market share, 2020 Neutral, Value Traps momentum. On the market has been around since 2004, has a very small market share, pacbio market share. Market if the deal eventually goes through systems maker posted big top- and bottom-line declines in development... An online or offline stock broker investors are enthusiastic about an analyst 's upgrade of the rather. Q2 Results is engaged in the UK $ 51.8M by 15 minutes manufacturing and marketing of integrated... - 2026 Research Use Only currently trading at 35.2 % premium to base! Have increased by 1,081.7 % and is now trading at 35.2 % premium to the base StockRank.! Of whether a stock price will go up is its track record of momentum in assessing share price movements Stockopedia... The consequences for both companies and on the market if the deal eventually through. A touchscreen control interface and computational hardware and software provided for Research Use.!